Joung-Liang Lan

Joung-Liang Lan

Auto-generated profile, based on publicly available information

Joung-Liang Lan

China Medical University Hospital Taichung Taiwan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Hsin-I Sam ChiangHsin-I Sam Chiang
Hsin-I Sam Chiang
JLJian-Rong Li
Jian-Rong Li
CLChun-Chi Liu
Chun-Chi Liu
PLPo-Yu Liu
Po-Yu Liu
HCHsin-Hua Chen
Hsin-Hua Chen
Der-Yuan ChenDer-Yuan Chen
Der-Yuan Chen
We aimed to investigate the association of gut microbiota with disease activity, inflammatory parameters, and auto-antibodies profile in rheumatoid arthritis (RA). A total of 138 RA patients and 21 healthy controls (HC) were enrolled. Fecal samples were collected for bacterial DNA extraction and 16S ribosome (r)RNA sequencing, followed by analyses of gut microbiota composition. Serum levels of tumor necrosis factor (TNF)-α, interleukin (IL)-6, and IL-17A were determined by using ELISA. Our results indicated that RA patients had lower diversity index, which reflects both evenness and richness of gut microbiota, compared to HC. The alpha-diversity was lower in anti-citrullinated peptide antibodies (ACPA)-positive patients than in HC. The phylum Verrucomicrobiae and genus Akkermansia were more abundant in patients compared to HC. There was increased relative abundance of Enterobacteriaceae as well as Klebsiella, and less abundance of Bifidobacterium in patients with high levels of TNF-α or IL-17A compared to those who had low levels of these cytokines. In addition, ACPA-positive patients had higher proportions of Blautia, Akkermansia, and Clostridiales than ACPA-negative patients. Gut dysbiosis in RA patients was presented as different microbial composition and its association with inflammatory parameters as well as ACPA seropositivity. These findings support the involvement of gut microbiota in RA pathogenesis.

Verified
Journal Article
Open access
PDF file
CYChin-An Yang
Chin-An Yang
Ju-Pi LiJu-Pi Li
Ju-Pi Li
JYJu-Chen Yen
Ju-Chen Yen
ILI-Lu Lai
I-Lu Lai
YHYu-Chen Ho
Yu-Chen Ho
JCJan-Gowth Chang
Jan-Gowth Chang
Monocytes/macrophages are important in orchestrating inflammatory responses. However, knowledge of the long noncoding RNA (lncRNA) regulation of monocytic cell differentiation and diseases remains limited. We aimed to elucidate the role of the 17 kb lncRNA noncoding transcript in T cells (NTT) in monocyte functions. Knockdown and chromatin immunoprecipitation (ChIP) assays in THP-1 cells (human monocytic leukemia cell line) revealed that NTT is regulated by the monocyte key transcription factor C/EBPβ and that it binds to the promoter of nearby gene PBOV1 via hnRNP-U. Overexpression of PBOV1 in THP-1 cells resulted in cell cycle G1 arrest, differentiation into macrophages, a marked increase in IL-10 and CXCL10 mRNA levels, and upregulation of the costimulatory molecules. In contrast to the downregulated NTT observed in lipopolysaccharide (LPS)-treated THP-1 cells, the C/EBPβ/NTT/PBOV1 axis was found to be hyperactivated in peripheral blood mononuclear cells (PBMCs) of first-time diagnosed untreated early rheumatoid arthritis (RA) patients, and their gene expression levels decreased markedly after treatment. Higher initial C/EBPβ/NTT/PBOV1 expression levels were associated with a trend of higher disease activity DAS28 scores. In conclusion, our study suggests that the lncRNA NTT is a regulator of inflammation in monocytes, and its activation participates in monocyte/macrophage differentiation and the pathogenesis of RA.

Verified
Journal Article
Open access
PDF file
CCChing-Kun Chang
Ching-Kun Chang
PCPo-Ku Chen
Po-Ku Chen
JLJoung-Liang Lan
Joung-Liang Lan
SCShih Hsin Chang
Shih Hsin Chang
THTsu-Yi Hsieh
Tsu-Yi Hsieh
Der-Yuan ChenDer-Yuan Chen
Der-Yuan Chen
L5, the most negatively charged subfraction of low-density lipoprotein (LDL), is implicated in atherogenesis, but the pathogenic association is relatively unexplored in patients with rheumatoid arthritis (RA). We examined the role of L5 LDL in macrophage foam cell formation and the association of L5 with CD11c expression in THP-1 cells and RA patients. Using quantitative real-time PCR, we determined mRNA expression levels of ITGAX, the gene for CD11c, a marker associated with vascular plaque formation and M1 macrophages in atherogenesis, in 93 RA patients. We also examined CD11c expression on THP-1 cells treated with L5 by flow cytometry analysis and the plasma levels of inflammatory mediators using a magnetic bead array. We found a dose-dependent upregulation of foam cell formation of macrophages after L5 treatment (mean ± SEM, 12.05 ± 2.35% in L5 (10 µg/mL); 50.13 ± 3.9% in L5 (25 µg/mL); 90.69 ± 1.82% in L5 (50 µg/mL), p < 0.01). Significantly higher levels of CD11c expression were observed in 30 patients with a high percentage of L5 in LDL (L5%) (0.0752 ± 0.0139-fold) compared to 63 patients with normal L5% (0.0446 ± 0.0054-fold, p < 0.05). CD11c expression levels were increased in the L5-treated group (30.00 ± 3.13% in L5 (10 µg/mL); 41.46 ± 2.77% in L5 (50 µg/mL), p < 0.05) and were positively correlated with plasma levels of interleukin (IL)-6 and IL-8. L5 augmented the expression of IL-6, IL-8, and tumor necrosis factor-α (TNF-α) on monocytes and macrophages. Our findings suggest that L5 may promote atherogenesis by augmenting macrophage foam cell formation, upregulating CD11c expression, and enhancing the expression levels of atherosclerosis-related mediators.

5 January 2023 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
CYChin‐An Yang
Chin‐An Yang
JLJu‐Pi Li
Ju‐Pi Li
YLYi‐Hua Lai
Yi‐Hua Lai
YHYa‐Ling Huang
Ya‐Ling Huang
CLChien‐Yu Lin
Chien‐Yu Lin
JLJoung‐Liang Lan
Joung‐Liang Lan

27 October 2022 in Clinical and Translational Science
Verified
Journal Article
Open access
KTKai‐Fa Teo
Kai‐Fa Teo
DCDer‐Yuan Chen
Der‐Yuan Chen
JHJeh‐Ting Hsu
Jeh‐Ting Hsu
YLYi‐Hua Lai
Yi‐Hua Lai
CCChing‐Kun Chang
Ching‐Kun Chang
JHJye-Lin Hsu
Jye-Lin Hsu
An efficient host immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) appears to be crucial for controlling and resolving this viral infection. However, many studies have reported autoimmune characteristics in severe COVID-19 patients. Moreover, clinical observations have revealed that COVID-19-associated acute distress respiratory syndrome shares many features in common with inflammatory myopathy including interstitial lung disease (ILD), most particularly rapidly progressive (RP)-ILD. This study explored this phenomenon by seeking to identify and characterize myositis-specific and related autoantibodies in 25 COVID-19 patients with mild or severe symptoms. Line blot analysis with the EUROLINE Myopathies Ag kit identified 9 (36%) patients with COVID-19 with one or more autoantibodies against several myositis-related antigens (Jo-1, Ku, Mi-2 beta, PL-7, PL-12, PM-Scl 75, PM-Scl 100, Ro-52, and SRP); no anti-MDA5 antibodies were detected. As the presence of antibodies identified by line blots was unrelated to disease severity, we further characterized the autoantibodies by radioimmunoassay, in which [S-35]methionine-labeled K562 cellular antigens were precipitated and visualized by gel electrophoresis. This result was confirmed by an immunoprecipitation assay and immunoblotting; 2 patients exhibited anti-Ku70 and anti-Ku80 antibodies. Our data suggest that it is necessary to use more than one method to characterize and evaluate autoantibodies in people recovered from COVID-19, in order to avoid misinterpreting those autoantibodies as diagnostic markers for autoimmune diseases.

16 May 2023 in LUTS: Lower Urinary Tract Symptoms
Verified
Journal Article
Closed access
HCHao Xiang Chen
Hao Xiang Chen
SCShih‐Hsin Chang
Shih‐Hsin Chang
Der-Yuan ChenDer-Yuan Chen
Der-Yuan Chen
JLJoung‐Liang Lan
Joung‐Liang Lan
KYKai‐Jieh Yeo
Kai‐Jieh Yeo
PWPo-Chang Wu
Po-Chang Wu